Mycophenolic acid glucuronide is transported by multidrug resistance-associated protein 2 and this transport is not inhibited by cyclosporine, tacrolimus or sirolimus

References

• Chen C, Slitt AL, Dieter MZ, Tanaka Y, Scheffer GL, Klaassen CD. (2005). Up-regulation of Mrp4 expression in kidney of Mrp2-deficient TR- rats. Biochem Pharmacol 70:1088–1095.
   PubMed Web of Science ®Google Scholar
• Chen J, Terada T, Ogasawara K, Katsura T, Inui K. (2008). Adaptive responses of renal organic anion transporter 3 (OAT3) during cholestasis. Am J Physiol Renal Physiol 295:F247–F252.
   PubMed Web of Science ®Google Scholar
• Davies NM, Grinyó J, Heading R, Maes B, Meier-Kriesche HU, Oellerich M. (2007). Gastrointestinal side effects of mycophenolic acid in renal transplant patients: a reappraisal. Nephrol Dial Transplant 22:2440–2448.
   PubMed Web of Science ®Google Scholar
• Evers R, Kool M, van Deemter L, Janssen H, Calafat J, Oomen LC, Paulusma CC, Oude Elferink RP, Baas F, Schinkel AH, Borst P. (1998). Drug export activity of the human canalicular multispecific organic anion transporter in polarized kidney MDCK cells expressing cMOAT (MRP2) cDNA. J Clin Invest 101:1310–1319.
   PubMed Web of Science ®Google Scholar
• Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, Dahlin A, Evers R, Fischer V, Hillgren KM, Hoffmaster KA, Ishikawa T, Keppler D, Kim RB, Lee CA, Niemi M, Polli JW, Sugiyama Y, Swaan PW, Ware JA, Wright SH, Yee SW, Zamek-Gliszczynski MJ, Zhang L; International Transporter Consortium. (2010). Membrane transporters in drug development. Nat Rev Drug Discov 9:215–236.
   PubMed Web of Science ®Google Scholar
• Goodman LS, Grosman-Rimon L, Mikuliszyn R. (2006). Carotid sinus pressure changes during push-pull maneuvers. Aviat Space Environ Med 77:921–928.
   Google Scholar
• Halloran PF. (2004). Immunosuppressive drugs for kidney transplantation. N Engl J Med 351:2715–2729.
   PubMed Web of Science ®Google Scholar
• Herédi-Szabó K, Glavinas H, Kis E, Méhn D, Báthori G, Veres Z, Kóbori L, von Richter O, Jemnitz K, Krajcsi P. (2009). Multidrug resistance protein 2-mediated estradiol-17beta-D-glucuronide transport potentiation: in vitro-in vivo correlation and species specificity. Drug Metab Dispos 37:794–801.
   PubMed Web of Science ®Google Scholar
• Hesselink DA, van Hest RM, Mathot RA, Bonthuis F, Weimar W, de Bruin RW, van Gelder T. (2005). Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2. Am J Transplant 5:987–994.
   PubMed Web of Science ®Google Scholar
• Ho RH, Kim RB. (2005). Transporters and drug therapy: implications for drug disposition and disease. Clin Pharmacol Ther 78:260–277.
   PubMed Web of Science ®Google Scholar
• Kalliokoski A, Niemi M. (2009). Impact of OATP transporters on pharmacokinetics. Br J Pharmacol 158:693–705.
   PubMed Web of Science ®Google Scholar
• Kobayashi M, Saitoh H, Kobayashi M, Tadano K, Takahashi Y, Hirano T. (2004). Cyclosporin A, but not tacrolimus, inhibits the biliary excretion of mycophenolic acid glucuronide possibly mediated by multidrug resistance-associated protein 2 in rats. J Pharmacol Exp Ther 309:1029–1035.
   PubMed Web of Science ®Google Scholar
• Kuypers DR, Vanrenterghem Y, Squifflet JP, Mourad M, Abramowicz D, Oellerich M, Armstrong V, Shipkova M, Daems J. (2003). Twelve-month evaluation of the clinical pharmacokinetics of total and free mycophenolic acid and its glucuronide metabolites in renal allograft recipients on low dose tacrolimus in combination with mycophenolate mofetil. Ther Drug Monit 25:609–622.
   PubMed Web of Science ®Google Scholar
• Lévesque E, Benoit-Biancamano MO, Delage R, Couture F, Guillemette C. (2008). Pharmacokinetics of mycophenolate mofetil and its glucuronide metabolites in healthy volunteers. Pharmacogenomics 9:869–879.
   PubMed Web of Science ®Google Scholar
• Lloberas N, Torras J, Cruzado JM, Andreu F, Oppenheimer F, Sánchez-Plumed J, Gentil MÁ, Brunet M, Ekberg H, Grinyó JM; Spanish Pharmacogenetic Symphony Substudy Group. (2011). Influence of MRP2 on MPA pharmacokinetics in renal transplant recipients-results of the Pharmacogenomic Substudy within the Symphony Study. Nephrol Dial Transplant 26:3784–3793.
   PubMed Web of Science ®Google Scholar
• Naesens M, Kuypers DR, Verbeke K, Vanrenterghem Y. (2006). Multidrug resistance protein 2 genetic polymorphisms influence mycophenolic acid exposure in renal allograft recipients. Transplantation 82:1074–1084.
   PubMed Web of Science ®Google Scholar
• Neerman MF, Boothe DM. (2003). A possible mechanism of gastrointestinal toxicity posed by mycophenolic acid. Pharmacol Res 47:523–526.
   PubMed Web of Science ®Google Scholar
• Nguyen T, Park JY, Scudiere JR, Montgomery E. (2009). Mycophenolic acid (cellcept and myofortic) induced injury of the upper GI tract. Am J Surg Pathol 33:1355–1363.
   Google Scholar
• Patel CG, Akhlaghi F. (2006). High-performance liquid chromatography method for the determination of mycophenolic acid and its acyl and phenol glucuronide metabolites in human plasma. Ther Drug Monit 28:116–122.
   PubMedGoogle Scholar
• Picard N, Marquet P. (2004). In vitro study of mycophenolic acid glucuronidation. Drug Metab Dispos 32:1524; author reply 1525.
   Google Scholar
• Picard N, Yee SW, Woillard JB, Lebranchu Y, Le Meur Y, Giacomini KM, Marquet P. (2010). The role of organic anion-transporting polypeptides and their common genetic variants in mycophenolic acid pharmacokinetics. Clin Pharmacol Ther 87:100–108.
   PubMed Web of Science ®Google Scholar
• Picard N, Levoir L, Lamoureux F, Yee SW, Giacomini KM, Marquet P. (2011). Interaction of sirolimus and everolimus with hepatic and intestinal organic anion-transporting polypeptide transporters. Xenobiotica 41:752–757.
   PubMed Web of Science ®Google Scholar
• Shaw LM, Nicholls A, Hale M, Armstrong VW, Oellerich M, Yatscoff R, Morris RE, Holt DW, Venkataramanan R, Haley J, Halloran P, Ettenger R, Keown P, Morris RG. (1998). Therapeutic monitoring of mycophenolic acid. A consensus panel report. Clin Biochem 31:317–322.
   Google Scholar
• Shipkova M, Armstrong VW, Weber L, Niedmann PD, Wieland E, Haley J, Tönshoff B, Oellerich M; German Study Group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients. (2002). Pharmacokinetics and protein adduct formation of the pharmacologically active acyl glucuronide metabolite of mycophenolic acid in pediatric renal transplant recipients. Ther Drug Monit 24:390–399.
   PubMed Web of Science ®Google Scholar
• Takekuma Y, Kakiuchi H, Yamazaki K, Miyauchi S, Kikukawa T, Kamo N, Ganapathy V, Sugawara M. (2007). Difference between pharmacokinetics of mycophenolic acid (MPA) in rats and that in humans is caused by different affinities of MRP2 to a glucuronized form. J Pharm Pharm Sci 10:71–85.
   PubMed Web of Science ®Google Scholar
• Westley IS, Brogan LR, Morris RG, Evans AM, Sallustio BC. (2006). Role of Mrp2 in the hepatic disposition of mycophenolic acid and its glucuronide metabolites: effect of cyclosporine. Drug Metab Dispos 34:261–266.
   PubMed Web of Science ®Google Scholar
• Wolff NA, Burckhardt BC, Burckhardt G, Oellerich M, Armstrong VW. (2007). Mycophenolic acid (MPA) and its glucuronide metabolites interact with transport systems responsible for excretion of organic anions in the basolateral membrane of the human kidney. Nephrol Dial Transplant 22:2497–2503.
   PubMed Web of Science ®Google Scholar
• Yamaguchi K, Murai T, Yabuuchi H, Kurosawa T. (2010). Measurement of transport activities of bile acids in human multidrug resistance-associated protein 3 using liquid chromatography-tandem mass spectrometry. Anal Sci 26:317–323.
   Google Scholar